Healthcare

Hong Kong’s tough path to biotech glory

After the rapid strides it has made as a destination for biotech listings in less than three years, Hong Kong now faces bigger challenges in overtaking New York.

Hong Kong may have made rapid strides as a top destination for the listing of biotechnology companies, but the path to the global crown it covets will likely neither be short nor easy.

¬ Haymarket Media Limited. All rights reserved.

Nice choice! This is premium FinanceAsia content.

Subscribers can sign in for full unlimited access.

New user? Sign up for a one-time 7-day unlimited free trial.

Questions?
See here for more information on licences and prices, or contact [email protected].

Share our publication on social media
Share our publication on social media